Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 22;20(5):804–814. doi: 10.1111/jcmm.12728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Altered numbers of IgG⁺ IgD⁻ >CD27⁺ memory B cells, CD138⁺ and IgG⁺ plasmablasts in UC patients after treatment with mesalazine. The numbers of IgG⁺ IgD⁻ CD27⁺ memory B cells and plasmablasts were compared in UC patients pre‐ and post‐treatment. Data are expressed as the real numbers of B cells or plasmablasts of individual subjects (n = 6 for A–C). The difference between pre‐ and post‐treatment patients was analysed by the Wilcoxon test. (A) The numbers of IgG⁺ IgD⁻ CD27⁺ memory B cells in individual patients pre‐ and post‐treatment. (B and C) The numbers of CD138⁺ CD38⁺ and IgG⁺ CD38⁺ plasmablasts in individual patients pre‐ and post‐treatment.